ADMA Biologics Set to Join SP SmallCap 600 Index
ADMA Stock | USD 21.18 0.12 0.56% |
About 57% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the SP SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The SP SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. ADMAs inclusion in the SP SmallCap 600 in
Read at finance.yahoo.com
ADMA Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
ADMA Biologics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
CDTX | Cidara Therapeutics | 16.91 | ||||
SANA | Sana Biotechnology | 11.06 | ||||
FATE | Fate Therapeutics | 10.63 | ||||
ANTX | AN2 Therapeutics | 8.94 | ||||
ATRA | Atara Biotherapeutics | 8.11 | ||||
IBIO | Ibio | 7.76 | ||||
MDGL | Madrigal Pharmaceuticals | 5.53 | ||||
MCRB | Seres Therapeutics | 5.48 | ||||
ETNB | 89bio | 4.53 | ||||
ACLX | Arcellx | 3.69 | ||||
AKBA | Akebia Ther | 3.30 | ||||
RCUS | Arcus Biosciences | 2.94 | ||||
INMB | INmune Bio | 2.31 | ||||
CRBU | Caribou Biosciences | 2.02 | ||||
PLX | Protalix Biotherapeutics | 1.81 | ||||
BCRX | BioCryst Pharmaceuticals | 1.47 | ||||
STOK | Stoke Therapeutics | 1.42 | ||||
PLRX | Pliant Therapeutics | 1.01 | ||||
VXRT | Vaxart | 1.64 | ||||
ANEB | Anebulo Pharmaceuticals | 2.67 | ||||
TFFP | Tff Pharmaceuticals | 2.86 | ||||
TNXP | Tonix Pharmaceuticals | 5.00 | ||||
XFOR | X4 Pharmaceuticals | 8.11 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |